Induction of apoptosis by anti-CD44 antibody in human chondrosarcoma cell line SW1353

Biomedical Research

Volumn 29, Issue 1, 2008, Pages 47-52

  Yoshida, Makoto ^a   Yasuda, Tadashi ^b   Hiramitsu, Teruko ^a   Iro, Hiromu ^a   Nakamura, Takashi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TENRI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HERMES ANTIGEN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY IM7; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARTILAGE CELL; CELL VIABILITY; CHONDROSARCOMA; CHROMATIN CONDENSATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHONDROCYTES; CHONDROSARCOMA; HUMANS; IMMUNOGLOBULIN G; PROPHASE;

EID: 41149173563     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.29.47     Document Type: Article

References (25)

1. Aruffo A, Stamenkovic I, Melnick M, Underhill CB and Seed B (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61, 1303-1313.
2. Bajorath J (2000) Molecular organization, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions. Proteins 39, 103-111.
3. Charrad R, Gadhoum Z, Qi J, Glachant A, Allouche M, Jasmin C, Chomienne C and Smadja-Joffe F (2002) Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood 99, 290-299.
4. Danial NN and Korsmeyer SJ (2004) Cell death: critical control points. Cell 116, 205-219.
5. Evans HL, Ayala AG and Romsdahl MM (1977) Prognostic factors in chondrosarcoma. of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer 40, 818-831.
6. Foger N, Marhaba R and Zoller M (2000) CD44 supports T cell proliferation and apoptosis by apposition of protein kinases. Eur J Immunol 30, 2888-2899.
7. Fong Y-C, Yang W-H, Hsu S-F, Hsu H-C, Tseng K-F, Hsu C-J, Lee C-Y and Scully SP (2007) 2-Methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells. J Orthop Res 25, 1106-1124.
8. Fujii K, Fujii Y, Hubscher S and Tanaka Y (2001) CD44 is the physiological trigger of Fas up-regulation on rheumatoid synovial cells. J Immunol 167, 1198-1203.
9. Günthert AR, Strater J, von Reyher U, Henne C, Joos S, Koretz K, Moldenhauer G, Krammer PH and Möller P (1996) Early detachment of colon carcinoma cells during CD95 (APO-1/Fas)-mediated apoptosis. I. De-adhesion from hyaluronate by shedding of CD44. J Cell Biol 134, 1089-1096.
10. Hauptschein RS, Sloan KE, Torella C, Moezzifard R, Giel-Moloney M, Zehetmeier C, Unger C, Ilag LL and Jay DG (2005) Functional proteomic screen identifies a modulating role for CD44 in death receptor-mediated apoptosis. Cancer Res 65, 1887-1896.
11. Henke C, Bitterman P, Roongta U, Ingbar D and Polunovsky V (1996) Induction of fibroblast apoptosis by anti-CD44 antibody: implications for the treatment of fibroproliferative lung dsease. Am J Pathol 149, 1639-1650.
12. Herr I and Debatin KM (2001) Cellular stress response and apoptosis in cancer therapy. Blood 98, 2603-2614.
13. Julovi SM, Yasuda T, Shimizu M, Hiramitsu T and Nakamura T (2004) Inhibition of interleukin-1β-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum 50, 516-525.
14. Klenke FM, Abdollahi A, Bertl E, Gebhard M-M, Ewerbeck V. Huber PE and Sckell A (2007) Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer 7, 49.
15. Kobayashi H, Suzuki M, Kanayama N, Nishida T, Takigawa M and Terao T (2002).CD44 stimulation by fragmented hyaluronic acid and induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells. Int J Cancer 102, 379-389.
16. Kubo T, Shimose S, Matsuo T, Tanaka K, Yasunaga Y, Sakai A and Ochi M (2006) Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. J Orthop Res 24, 1138-1144.
17. Martin TA, Harrison G, Mansel RE and Jiang WG (2003) The role of the CD44/ezrin complex in cancer matastasis. Crit Rev Oncol Hematol 46, 165-186.
18. Mielgo A, van Driel M, Bloem A, Landmann L and Guenthert U (2006) A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ 13, 465-477.
19. Ozaki T, Lindner N, Hillmann A, Rodl R, Blasius S and Winkelmann W (1996) Influence of intralesional surgery on treatment outcome of chondrosarcoma. Cancer 77, 1292-1297.
20. Ponta H, Sherman L and Heirlich PA (2003) CD44: from adhesion molecule to signalling regulators. Nat Rev Mol Cell Biol 4, 33-45.
21. Schmitt CA (2003) Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nat Rev Cancer 3, 286-295.
22. Sheth DS, Yasko AW, Johnson ME, Ayala AG, Murray JA and Romsdahl MM (1996) Chondrosarcoma of the pelvis. Prognostic factors for 67 patients treated with definitive surgery. Cancer 78, 745-750.
23. Takazoe K, Tesch GH, Hill PA, Hurst LA, Jun Z, Lan HY, Atkins RC and Nikolic-Paterson DJ (2000) CD44-mediated neutrophil apoptosis in the rat. Kidney Int 58, 1920-1930.
24. Tian B, Takasu T and Henke C (2000) Functional role of cyclin A on induction of fibroblast apoptosis due to ligation of CD44 matrix receptor by anti-CD44 antibody. Exp Cell Res 257, 135-144.
25. Wang X, DeFrances MC, Dai Y, Pediaditakis P, Johnson C, Bell A, Michalopoulos GK and Zarnegar R (2002) A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell 9, 411-421.